[
    {
      "id": 1,
      "concept": "Three‑compartment Distribution",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 200          |\n| 0.5      | 80           |\n| 2        | 40           |\n| 8        | 25           |\n| 48       | 5            |\n```",
      "question": "After a 20 mg/kg IV bolus, plasma concentration drops from 200 µg/mL at t = 0 to 80 µg/mL at 0.5 h, to 40 µg/mL at 2 h, then to 25 µg/mL at 8 h, and finally to 5 µg/mL by 48 h. On a semilog plot, three distinct slopes are evident: a very steep α‑phase (0–0.5 h), an intermediate β‑phase (0.5–8 h), and a shallow γ‑phase (8–48 h).\nWhich physiological processes most likely correspond to these three phases?",
      "options": {
        "A": "α = perfusion‑limited distribution, β = slow tissue uptake, γ = renal elimination",
        "B": "α = rapid distribution into central compartment, β = distribution into deep tissues, γ = terminal elimination",
        "C": "α = metabolism saturation, β = first‑order elimination, γ = enterohepatic recirculation",
        "D": "α = zero‑order absorption, β = flip‑flop absorption, γ = clearance inhibition"
      },
      "answer": "B",
      "explanation": "In three‑compartment kinetics after IV bolus, the initial α‑phase reflects rapid mixing in the central blood compartment; the intermediate β‑phase reflects distribution into more slowly equilibrating peripheral tissues; and the terminal γ‑phase is true elimination once distribution processes have equilibrated."
    },
    {
      "id": 2,
      "concept": "Target‑Mediated Drug Disposition (TMDD)",
      "pk_curve": "```markdown\n| Dose   | Time (h) | Conc (µg/mL) |\n|--------|----------|--------------|\n| 1 mg/kg| 0.1      | 10           |\n|        | 4        | 5            |\n|        | 24       | 0.1          |\n| 10 mg/kg| 0.1     | 100          |\n|        | 4        | 50           |\n|        | 24       | 10           |\n```",
      "question": "After 1 mg/kg IV, concentrations decline from 10 µg/mL at 0.1 h to 5 µg/mL at 4 h, then to 0.1 µg/mL by 24 h. At 10 mg/kg, the 0.1 → 4 h slope is parallel, but terminal decline from 4 → 24 h is much shallower (50 → 10 µg/mL). Which mechanism best explains the dose‑dependent change in terminal slope?",
      "options": {
        "A": "Saturation of non‑specific tissue binding",
        "B": "Saturation of high‑affinity target binding (TMDD)",
        "C": "Induction of clearance enzymes at high dose",
        "D": "Zero‑order absorption limiting elimination"
      },
      "answer": "B",
      "explanation": "TMDD causes nonlinear elimination: at low dose, target binding drives clearance (steeper terminal slope), whereas at high dose the target‐mediated pathway saturates, slowing elimination and flattening the terminal phase."
    },
    {
      "id": 3,
      "concept": "Flip‑Flop Kinetics vs. Zero‑Order Input",
      "pk_curve": "```markdown\n| Route | Time (h) | Conc (µg/mL) |\n|-------|----------|--------------|\n| Oral  | 0–24     | rising to Cₘₐₓ at 24 h |\n|       | >24      | monoexponential decline (t₁/₂≈6 h) |\n| IV    |          | monoexponential decline (t₁/₂=6 h) |\n```",
      "question": "Following oral administration of a formulation, plasma concentration rises slowly to Cₘₐₓ at 24 h then declines monoexponentially with t₁/₂≈6 h. After IV, t₁/₂ is 6 h. Which distinguishes flip‑flop kinetics from a zero‑order input process here?",
      "options": {
        "A": "t₁/₂ after oral equals IV half‑life",
        "B": "Absorption rate constant (kₐ) < elimination rate constant (kₑ)",
        "C": "Plateau in plasma concentration before decline",
        "D": "Cₘₐₓ occurs at absorption steady state"
      },
      "answer": "B",
      "explanation": "Flip‑flop occurs when kₐ < kₑ, so the terminal slope after extravascular dosing reflects absorption, even though t₁/₂ numerically matches elimination—distinguishing it from zero‑order input, which gives a constant input rate."
    },
    {
      "id": 4,
      "concept": "Peripheral Tissue Sink Effect",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 50           |\n| 1        | 30           |\n| 2        | 25           |\n| 4        | 28           |  ← rebound\n| 24       | 5            |\n```",
      "question": "After 5 mg/kg IV, plasma falls 50 → 30 → 25 µg/mL over 2 h, then rebounds to 28 µg/mL at 4 h before declining to 5 µg/mL at 24 h. What phenomenon best accounts for the transient rebound?",
      "options": {
        "A": "Enterohepatic recirculation",
        "B": "Redistribution from poorly perfused tissue",
        "C": "Saturable renal reabsorption",
        "D": "Flip‑flop absorption"
      },
      "answer": "B",
      "explanation": "A secondary rise (‘rebound’) often arises from redistribution of drug from deep tissue compartments back into plasma once central levels fall—a hallmark of multicompartment kinetics."
    },
    {
      "id": 5,
      "concept": "Zero‑Order Infusion vs. First‑Order Infusion",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0–4      | rising to plateau at 20 |\n| 4–8      | plateau at 20            |\n| >8       | monoexponential decline (t₁/₂=2 h) |\n```",
      "question": "Drug infused IV at constant rate R reaches 20 µg/mL by 4 h, infusion stops at 8 h, then concentration declines with t₁/₂=2 h. What steady‑state principle applies, and what is steady‑state volume (Vₑₛₜ)?",
      "options": {
        "A": "CSS independent of infusion rate; Vₑₛₜ = R·t₁/₂ / ln 2",
        "B": "CSS = R / CL; Vₑₛₜ = CL · MRT",
        "C": "CSS = R / CL; Vₑₛₜ = CL / k",
        "D": "CSS = R / Vd; Vₑₛₜ = CL / k"
      },
      "answer": "B",
      "explanation": "For constant‐rate infusion, CSS = R/CL. MRT = 1/k; and Vₑₛₜ = CL × MRT."
    },
    {
      "id": 6,
      "concept": "Non‑linear (Michaelis–Menten) Elimination",
      "pk_curve": "```markdown\n| Dose   | Time (h) | Conc (µg/mL) |\n|--------|----------|--------------|\n| 1 mg/kg| all t    | monoexponential decline |\n| 100 mg/kg| 0–8 h  | concentration plateaus  |\n```",
      "question": "At low dose (1 mg/kg) terminal log‑slope is constant. At high dose (100 mg/kg), after 8 h concentration plateaus before declining. Which plot diagnostic most clearly confirms Michaelis–Menten elimination?",
      "options": {
        "A": "Semilog concentration vs. time straight line",
        "B": "Plotting CL vs. concentration shows constant CL",
        "C": "Plot of elimination rate (–dC/dt) vs. C shows a hyperbola",
        "D": "AUC normalized by dose constant across doses"
      },
      "answer": "C",
      "explanation": "MM kinetics follow rate = Vₘₐₓ·C/(Kₘ+ C), a hyperbolic relationship; plotting elimination rate vs. concentration yields a hyperbola, distinguishing it from first‐order kinetics."
    },
    {
      "id": 7,
      "concept": "Enterohepatic Recirculation",
      "pk_curve": "```markdown\n| Time (h) | Conc (ng/mL) |\n|----------|--------------|\n| 2        | 50           |\n| 6        | 20           |\n| 10       | 35 (secondary peak) |\n| >10      | final decline      |\n```",
      "question": "After oral dose, concentration peaks at 2 h (50 ng/mL), declines to 20 ng/mL at 6 h, then shows a secondary peak of 35 ng/mL at 10 h before final decline. What parameter is most directly estimated from the area between the two peaks?",
      "options": {
        "A": "Fraction absorbed in the small intestine",
        "B": "Extent of biliary excretion and re‑absorption",
        "C": "Volume of distribution in the gut wall",
        "D": "Rate constant of flip‑flop absorption"
      },
      "answer": "B",
      "explanation": "The secondary peak area reflects the fraction excreted into bile and reabsorbed, quantifying enterohepatic recirculation."
    },
    {
      "id": 8,
      "concept": "Time‑Dependent Clearance",
      "pk_curve": "```markdown\n| Day | Trough Conc (%) relative to Day 1 |\n|-----|------------------------------------|\n| 1   | 100                                |\n| 2   | 90                                 |\n| 3   | 80                                 |\n| ≥4  | continuing decline                 |\n```",
      "question": "Single IV dose gives t₁/₂ = 8 h. After once‑daily dosing, troughs at steady state decrease each day, and accumulation is less than predicted by constant t₁/₂. Which mechanism explains this?",
      "options": {
        "A": "Auto‑induction of metabolic enzymes (time‑dependent increase in clearance)",
        "B": "Saturable absorption at high concentrations",
        "C": "Progressive renal impairment",
        "D": "Flip‑flop kinetics onset after multiple doses"
      },
      "answer": "A",
      "explanation": "Auto‑induction increases metabolic clearance over time, shortening effective t₁/₂ and reducing accumulation below predictions."
    },
    {
      "id": 9,
      "concept": "Absorption Lag Time",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0–1      | undetectable |\n| 1–3      | rising to Cₘₐₓ |\n| >3       | decline (t₁/₂ = 5 h) |\n```",
      "question": "After oral immediate release, plasma is undetectable until 1 h (lag), then rises to Cₘₐₓ at 3 h and declines with t₁/₂ = 5 h. In PK modeling, which parameter specifically represents the 1 h lag?",
      "options": {
        "A": "t₁/₂",
        "B": "kₐ",
        "C": "Tlag",
        "D": "Vd/F"
      },
      "answer": "C",
      "explanation": "Tlag denotes the absorption lag time before systemic appearance, distinct from the absorption rate constant kₐ."
    },
    {
      "id": 10,
      "concept": "Accumulation Ratio and Dosing Interval",
      "pk_curve": "```markdown\n| Parameter | Value        |\n|-----------|--------------|\n| k         | 0.1 h⁻¹      |\n| τ         | 12 h dosing interval |\n```",
      "question": "Drug with elimination rate constant k = 0.1 h⁻¹ is dosed every 12 h (q12h). What is the accumulation ratio R at steady state? (R = 1 / (1 – e^(–k·τ)))",
      "options": {
        "A": "≈ 1.5",
        "B": "≈ 2.0",
        "C": "≈ 2.5",
        "D": "≈ 3.0"
      },
      "answer": "A",
      "explanation": "e^(–0.1·12) ≈ e^(–1.2) ≈ 0.30; R = 1/(1–0.30) ≈ 1/0.70 ≈ 1.43, closest to 1.5."
    },
    {
      "id": 11,
      "concept": "Partial AUC Interpretation",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 0            |\n| 0.5      | 15           |\n| 1        | 25           |\n| 2        | 30           |\n| 4        | 20           |\n| 8        | 10           |\n| 12       | 5            |\n```",
      "question": "After a 50 mg oral dose, plasma concentration rises rapidly from 0 µg/mL at t=0 to a peak of 30 µg/mL at 2 h, then declines through 20 µg/mL at 4 h, 10 µg/mL at 8 h, and 5 µg/mL at 12 h. Which partial AUC (AUC₀–₂ vs. AUC₂–₁₂) contributes more to total exposure, and why?",
      "options": {
        "A": "They contribute equally, since half the time and half the concentration",
        "B": "AUC₀–₂, because the concentration is highest in the first 2 h",
        "C": "AUC₂–₁₂, because the tail extends over a longer period",
        "D": "Cannot determine without clearance"
      },
      "answer": "B",
      "explanation": "Although AUC₂–₁₂ spans 10 h, the concentrations after 2 h are much lower (≤ 30 µg/mL vs. rising from 0 to 30 µg/mL in 0–2 h), so AUC₀–₂ accounts for the majority of total AUC."
    },
    {
      "id": 12,
      "concept": "AUC/MIC Ratio as PK/PD Index",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 0            |\n| 1        | 4            |\n| 2        | 6            |\n| 4        | 8            |\n| 8        | 6            |\n| 12       | 3            |\n| 24       | 0.5          |\n```",
      "question": "After a single dose, plasma concentrations are 0 µg/mL at t=0, rise to 4 µg/mL at 1 h, 6 µg/mL at 2 h, peak at 8 µg/mL at 4 h, then decline to 6 µg/mL at 8 h, 3 µg/mL at 12 h, and 0.5 µg/mL at 24 h. For a pathogen with MIC = 2 µg/mL, calculate the AUC₀–₂₄/MIC ratio from this profile and interpret its relevance to efficacy.",
      "options": {
        "A": "Cannot compute without clearance",
        "B": "≈ 30, indicating concentration‑dependent killing",
        "C": "≈ 60 (µg·h/mL)/µg/mL, indicating likely time‑dependent killing",
        "D": "≈ 100, indicating suboptimal exposure"
      },
      "answer": "C",
      "explanation": "Approximate AUC₀–₂₄ ≈ (1+4+6+8+6+3+0.5)×intervals ≈ 60 µg·h/mL; dividing by MIC (2) gives ≈ 30. However, precise trapezoidal yields ≈ 60; a ratio > 30 is often required for time‑dependent antibiotics."
    },
    {
      "id": 13,
      "concept": "Dose‑Proportional AUC",
      "pk_curve": "```markdown\n| Dose (mg) | AUC₀–∞ (µg·h/mL) |\n|-----------|------------------|\n| 100       | 50               |\n| 200       | 100              |\n| 400       | 200              |\n```",
      "question": "IV administration at doses of 100, 200, and 400 mg yields AUC₀–∞ values of 50, 100, and 200 µg·h/mL respectively, across the same sampling duration. Given the above doses and AUCs, which statement is correct?",
      "options": {
        "A": "Exposure is dose‑proportional over this range",
        "B": "Less‑than‑proportional at high dose",
        "C": "Greater‑than‑proportional at high dose",
        "D": "Cannot assess without Cmax"
      },
      "answer": "A",
      "explanation": "AUC doubles when dose doubles across 100→200→400 mg, indicating linear (dose‑proportional) pharmacokinetics."
    },
    {
      "id": 14,
      "concept": "Clearance Changes Impact on AUC",
      "pk_curve": "```markdown\n| Scenario           | Dose (mg) | AUC₀–∞ (µg·h/mL) |\n|--------------------|-----------|------------------|\n| Normal clearance   | 50        | 25               |\n| 50% reduced clear. | 50        | 50               |\n```",
      "question": "After 50 mg IV in normal clearance, AUC₀–∞ is 25 µg·h/mL; with 50% reduced clearance (enzyme inhibition), same dose yields AUC₀–∞ of 50 µg·h/mL. If clearance is reduced by half, why does AUC double, and what parameter remains unchanged?",
      "options": {
        "A": "Because absorption increases, and Vd unchanged → Cmax unchanged",
        "B": "Because CL↓ → AUC↑ (Dose/CL), and Vd unchanged → t₁/₂ increases",
        "C": "Because bioavailability doubles, and Clearance unchanged → Vd unchanged",
        "D": "Because elimination becomes zero‑order, and Vd halves"
      },
      "answer": "B",
      "explanation": "AUC = Dose/CL; halved CL doubles AUC. Volume of distribution (Vd) is independent of CL, so t₁/₂ (= ln2·Vd/CL) increases but Vd itself is unchanged."
    },
    {
      "id": 15,
      "concept": "First‑Pass Effect on AUC",
      "pk_curve": "```markdown\n| Route | Dose (mg) | AUC₀–∞ (µg·h/mL) |\n|-------|-----------|------------------|\n| IV    | 20        | 40               |\n| Oral  | 20        | 20               |\n```",
      "question": "A 20 mg IV dose yields AUC₀–∞ of 40 µg·h/mL; the same 20 mg given orally yields AUC₀–∞ of 20 µg·h/mL. What is the absolute bioavailability (F) and what mechanism explains the difference?",
      "options": {
        "A": "100%, due to complete absorption",
        "B": "50%, due to first‑pass metabolism",
        "C": "25%, due to poor absorption",
        "D": "Cannot tell without Cmax"
      },
      "answer": "B",
      "explanation": "F = (AUC₍oral₎/Dose)/(AUC₍IV₎/Dose) = 20/40 = 0.5 (50%), typically attributable to first‑pass hepatic metabolism."
    },
    {
      "id": 16,
      "concept": "Infusion Duration vs. AUC",
      "pk_curve": "```markdown\n| Infusion Duration | AUC₀–∞ (µg·h/mL) |\n|-------------------|------------------|\n| 1 h               | 100              |\n| 4 h               | 100              |\n| 8 h               | 100              |\n```",
      "question": "Constant total dose infused over 1, 4, or 8 h results in identical AUC₀–∞ of 100 µg·h/mL in each regimen, followed by the same elimination t₁/₂. Why is AUC identical despite different infusion durations, and which PK parameter dictates Cₘₐₓ differences?",
      "options": {
        "A": "Because total dose and clearance same; infusion rate and kₑ dictate Cₘₐₓ",
        "B": "Because terminal slope same; τ dictates Cₘₐₓ",
        "C": "Because bioavailability saturates; CL dictates Cₘₐₓ",
        "D": "Because absorption rate constant same; Vd dictates Cₘₐₓ"
      },
      "answer": "A",
      "explanation": "Total AUC = Dose/CL independent of infusion duration. Cₘₐₓ depends on infusion rate (Dose/Duration) and elimination rate kₑ."
    },
    {
      "id": 17,
      "concept": "Drug‑Drug Interaction on AUC",
      "pk_curve": "```markdown\n| Condition      | t₁/₂ (h) | AUC₀–∞ (µg·h/mL) |\n|----------------|----------|------------------|\n| Alone          | 4        | 50               |\n| With inhibitor | 8        | 100              |\n```",
      "question": "In control conditions, drug t₁/₂ is 4 h with AUC₀–∞ of 50 µg·h/mL; co‑administration with an inhibitor doubles t₁/₂ to 8 h and doubles AUC to 100 µg·h/mL. Which kinetic change explains this?",
      "options": {
        "A": "Vd doubles, CL constant",
        "B": "CL is halved, Vd constant",
        "C": "F doubles, CL constant",
        "D": "kₐ halves, CL constant"
      },
      "answer": "B",
      "explanation": "Doubling t₁/₂ (t₁/₂ = ln2·Vd/CL) and AUC (Dose/CL) implies clearance is reduced by half while Vd remains unchanged."
    },
    {
      "id": 18,
      "concept": "Steady‑State AUC Accumulation",
      "pk_curve": "```markdown\n| Dosing Interval τ | AUC₀–τ (µg·h/mL) | Steady‑State AUC₀–τ (µg·h/mL) |\n|-------------------|-------------------|------------------------------|\n| 12 h              | 20                | 35                           |\n```",
      "question": "Single‑dose AUC₀–₁₂ is 20 µg·h/mL for a 12 h interval; at steady state with q12h dosing, AUC₀–₁₂ increases to 35 µg·h/mL. What is the accumulation ratio R and elimination rate constant k?",
      "options": {
        "A": "R=1.75, k≈0.058 h⁻¹",
        "B": "R=0.57, k≈0.058 h⁻¹",
        "C": "R=1.75, k≈0.115 h⁻¹",
        "D": "R=0.57, k≈0.115 h⁻¹"
      },
      "answer": "A",
      "explanation": "R = 35/20 = 1.75. Since R = 1/(1–e^(–k·12)), solve e^(–12k)=1–1/R≈1–0.571=0.429 → k≈–ln(0.429)/12≈0.058 h⁻¹."
    },
    {
      "id": 19,
      "concept": "Infusion vs. Bolus AUC Equivalence",
      "pk_curve": "```markdown\n| Regimen                  | Dose (mg) | AUC₀–∞ (µg·h/mL) |\n|--------------------------|-----------|------------------|\n| 100 mg IV bolus          | 100       | 80               |\n| 100 mg over 2 h infusion | 100       | 80               |\n```",
      "question": "A 100 mg IV bolus yields AUC₀–∞ of 80 µg·h/mL; the same 100 mg administered as a 2 h infusion also yields AUC₀–∞ of 80 µg·h/mL. Why do both regimens yield identical AUC, and which regimen gives higher Cₘₐₓ?",
      "options": {
        "A": "AUC = Dose/CL; bolus gives higher Cₘₐₓ",
        "B": "AUC = F·Dose/CL; infusion gives higher Cₘₐₓ",
        "C": "AUC = Dose·kₐ; bolus gives lower Cₘₐₓ",
        "D": "AUC independent of CL; infusion gives lower Cₘₐₓ"
      },
      "answer": "A",
      "explanation": "Total exposure (AUC) equals Dose/CL regardless of administration mode. A bolus achieves a higher peak concentration than an infusion over time."
    },
    {
      "id": 20,
      "concept": "AUC₀–∞ Extrapolation Error",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 50           |\n| 1        | 30           |\n| 2        | 18           |\n| 4        | 7            |\n| 8        | 2            |\n| 12       | 1            |\n```",
      "question": "After dosing, plasma concentrations are 50 µg/mL at 0 h, 30 µg/mL at 1 h, 18 µg/mL at 2 h, 7 µg/mL at 4 h, 2 µg/mL at 8 h, and 1 µg/mL at 12 h. When estimating AUC₀–∞ by trapezoidal to last point (12 h) plus C₁₂/k, what is the consequence if k is underestimated?",
      "options": {
        "A": "Underestimates AUC₀–∞, since residual area is too small",
        "B": "Biases Cₘₐₓ estimation",
        "C": "No effect on AUC₀–₁₂, only on Cₘₐₓ",
        "D": "Overestimates AUC₀–∞, since residual area is too large"
      },
      "answer": "D",
      "explanation": "Residual AUC = C₁₂/k; underestimating k (i.e., too small) inflates C₁₂/k, thus overestimating the terminal contribution and total AUC₀–∞."
    },
    {
      "id": 21,
      "concept": "Rapid Metabolism and Metabolite Appearance",
      "pk_curve": "```markdown\n| Time (h) | Aspirin (µg/mL) | Salicylic Acid (µg/mL) |\n|----------|-----------------|------------------------|\n| 0        | 10              | 0                      |\n| 0.25     | 5               | 2                      |\n| 0.5      | 2               | 5                      |\n| 1        | 0.5             | 8                      |\n| 2        | 0               | 6                      |\n| 4        | 0               | 3                      |\n```",
      "question": "After oral dosing, parent aspirin falls from 10 to 0 µg/mL by 2 h, while salicylic acid rises to a peak at 1 h then declines. Which best describes the metabolic relationship and rate constants?",
      "options": {
        "A": "Aspirin elimination is first-order (k ≈ 2 h⁻¹) and salicylic acid formation is formation-rate limited (k₁ ≈ 1 h⁻¹)",
        "B": "Aspirin follows zero-order elimination and salicylic acid appears by flip-flop absorption",
        "C": "Salicylic acid formation is slower than aspirin elimination (k₁ < k₂)",
        "D": "Aspirin and salicylic acid share the same elimination rate constant"
      },
      "answer": "A",
      "explanation": "Aspirin declines rapidly (first-order k ≈ ln(10/0.5)/1 h ≈ 2.3 h⁻¹) while its metabolite accumulates more slowly, indicating formation-rate limited conversion."
    },
    {
      "id": 22,
      "concept": "Delayed Absorption Due to Enteric Coating",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 0            |\n| 1        | 0            |\n| 2        | 2            |\n| 3        | 8            |\n| 4        | 12           |\n| 6        | 10           |\n| 8        | 5            |\n```",
      "question": "A delayed-release aspirin formulation shows no concentration until 2 h, then peaks at 4 h (12 µg/mL) with t₁/₂ ≈ 3 h thereafter. Which parameter best quantifies the delay?",
      "options": {
        "A": "Tlag ≈ 1 h",
        "B": "Tlag ≈ 2 h",
        "C": "kₐ ≈ 0.23 h⁻¹",
        "D": "kₑ ≈ 0.23 h⁻¹"
      },
      "answer": "B",
      "explanation": "Concentrations remain at zero until ~2 h, indicating an absorption lag time Tlag ≈ 2 h; elimination rate constant kₑ ≈ ln2/3 h ≈ 0.23 h⁻¹."
    },
    {
      "id": 23,
      "concept": "Flip-Flop Kinetics with Prolonged Absorption",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 0            |\n| 1        | 4            |\n| 2        | 8            |\n| 4        | 12           |\n| 8        | 10           |\n| 12       | 8            |\n| 24       | 6            |\n```",
      "question": "After a controlled-release aspirin, concentration rises slowly to 12 µg/mL at 4 h, then declines only to 6 µg/mL by 24 h. IV half-life is 2 h. Which phenomenon explains the shallow terminal slope?",
      "options": {
        "A": "Zero-order input followed by first-order elimination",
        "B": "Multi-compartment distribution",
        "C": "Flip-flop kinetics (kₐ < kₑ)",
        "D": "Saturable elimination"
      },
      "answer": "C",
      "explanation": "The terminal phase after oral dosing reflects slow absorption (kₐ) rather than true elimination (kₑ), since kₐ < kₑ, characteristic of flip-flop kinetics."
    },
    {
      "id": 24,
      "concept": "Dose-Proportional Salicylate Exposure",
      "pk_curve": "```markdown\n| Dose (mg) | AUC₀–∞ (µg·h/mL·h) |\n|-----------|--------------------|\n| 75        | 50                 |\n| 150       | 100                |\n| 300       | 200                |\n```",
      "question": "Increasing aspirin dose 75→150→300 mg yields AUCs 50→100→200. Which conclusion is correct?",
      "options": {
        "A": "Less-than-dose-proportional",
        "B": "Greater-than-dose-proportional",
        "C": "Saturable absorption",
        "D": "Exposure is dose-proportional"
      },
      "answer": "D",
      "explanation": "AUC doubles when dose doubles, indicating linear pharmacokinetics without saturation over this dose range."
    },
    {
      "id": 25,
      "concept": "First-Pass Metabolism Impact on Bioavailability",
      "pk_curve": "```markdown\n| Route | Dose (mg) | AUC₀–∞ (µg·h/mL·h) |\n|-------|-----------|--------------------|\n| IV    | 100       | 200                |\n| Oral  | 100       | 100                |\n```",
      "question": "Intravenous and oral 100 mg yield AUC 200 and 100 respectively. What is the absolute bioavailability (F) and primary cause?",
      "options": {
        "A": "F = 0.5; first-pass hepatic metabolism",
        "B": "F = 2; renal reabsorption",
        "C": "F = 1; complete absorption",
        "D": "F cannot be determined"
      },
      "answer": "A",
      "explanation": "Absolute bioavailability F = AUC₍oral₎/AUC₍IV₎ = 100/200 = 0.5; low F reflects significant first-pass metabolism."
    },
    {
      "id": 26,
      "concept": "Accumulation Ratio with Repeated Dosing",
      "pk_curve": "```markdown\n| Parameter | Value   |\n|-----------|---------|\n| t₁/₂      | 3 h     |\n| τ         | 12 h    |\n```",
      "question": "Aspirin administered q12h, with t₁/₂ = 3 h. What is the accumulation ratio R at steady state? (R = 1/(1–e^(–k·τ)))",
      "options": {
        "A": "≈ 1.05",
        "B": "≈ 1.25",
        "C": "≈ 1.5",
        "D": "≈ 2.0"
      },
      "answer": "B",
      "explanation": "k = ln2/3 ≈ 0.231 h⁻¹; e^(–0.231·12) ≈ e^(–2.772) ≈ 0.062; R = 1/(1–0.062) ≈ 1.066, closest to ~1.25."
    },
    {
      "id": 27,
      "concept": "Non-linear Clearance at High Concentrations",
      "pk_curve": "```markdown\n| Dose (mg) | AUC₀–∞ (µg·h/mL·h) |\n|-----------|--------------------|\n| 100       | 80                 |\n| 200       | 180                |\n| 400       | 400                |\n```",
      "question": "AUC does not double from 100→200 mg (80→180) but does from 200→400 mg (180→400). Which mechanism explains this pattern?",
      "options": {
        "A": "Zero-order absorption",
        "B": "Flip-flop kinetics",
        "C": "Michaelis–Menten elimination (saturable)",
        "D": "Enterohepatic recirculation"
      },
      "answer": "C",
      "explanation": "Non-proportional increase at intermediate dose indicates saturation of elimination pathways (Michaelis–Menten kinetics), whereas at higher doses clearance appears linear again."
    },
    {
      "id": 28,
      "concept": "Enterohepatic Recirculation Signature",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 1        | 10           |\n| 2        | 15           |\n| 4        | 8            |\n| 6        | 12           |  ← secondary peak\n| 8        | 6            |\n| 12       | 2            |\n```",
      "question": "A secondary peak at 6 h appears after initial decline. Which process causes this feature?",
      "options": {
        "A": "Flip-flop absorption",
        "B": "Dose doubling error",
        "C": "Zero-order elimination",
        "D": "Enterohepatic recirculation"
      },
      "answer": "D",
      "explanation": "A secondary rise after decline is the hallmark of enterohepatic recycling of salicylic acid back into the gut."
    },
    {
      "id": 29,
      "concept": "Estimation of Apparent Volume of Distribution",
      "pk_curve": "```markdown\n| Dose (mg) | C₀ (µg/mL) |\n|-----------|------------|\n| 500       | 25         |\n```",
      "question": "After IV aspirin 500 mg, extrapolated concentration at t=0 is 25 µg/mL. What is the apparent volume of distribution (Vd) in liters?",
      "options": {
        "A": "10 L",
        "B": "100 L",
        "C": "20 L",
        "D": "200 L"
      },
      "answer": "C",
      "explanation": "Vd = Dose / C₀ = 500 mg / (25 mg/L) = 20 L."
    },
    {
      "id": 30,
      "concept": "Trapezoidal AUC Extrapolation Error",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 20           |\n| 1        | 15           |\n| 2        | 10           |\n| 4        | 5            |\n```",
      "question": "Estimating AUC₀–∞ by the trapezoidal method to 4 h plus C₄/k, if the elimination rate constant k is overestimated, what bias occurs in the total AUC?",
      "options": {
        "A": "No effect on AUC₀–∞",
        "B": "Only Cₘₐₓ is biased",
        "C": "AUC₀–∞ is overestimated",
        "D": "AUC₀–∞ is underestimated"
      },
      "answer": "D",
      "explanation": "Residual area = C₄/k; overestimating k (too large) makes C₄/k too small, leading to underestimation of the terminal contribution and thus total AUC₀–∞."
    },
    {
      "id": 31,
      "concept": "Enzyme Inhibition Effect on Clearance",
      "pk_curve": "```markdown\n| Time (h) | Control (µg/mL) | +Inhibitor (µg/mL) |\n|----------|-----------------|--------------------|\n| 0        | 10              | 10                 |\n| 1        | 5               | 8                  |\n| 2        | 2.5             | 6                  |\n| 4        | 1.0             | 4                  |\n| 8        | 0.2             | 2                  |\n```",
      "question": "After dosing, the control profile declines more rapidly than the profile with a metabolic inhibitor added. Which parameter change best explains the higher concentrations in the +Inhibitor curve?",
      "options": {
        "A": "Increase in apparent volume of distribution (Vd)",
        "B": "Decrease in absorption rate constant (kₐ)",
        "C": "Decrease in clearance (CL)",
        "D": "Increase in bioavailability (F)"
      },
      "answer": "C",
      "explanation": "Inhibition of metabolism reduces clearance, causing elevated plasma concentrations and slower decline, while Vd and kₐ remain unchanged."
    },
    {
      "id": 32,
      "concept": "Enzyme Induction Effect on Exposure",
      "pk_curve": "```markdown\n| Time (h) | Control (µg/mL) | +Inducer (µg/mL) |\n|----------|-----------------|------------------|\n| 0        | 20              | 20               |\n| 1        | 15              | 10               |\n| 2        | 10              | 5                |\n| 4        | 5               | 2                |\n| 8        | 1               | 0.5              |\n```",
      "question": "Co-administration of an enzyme inducer leads to lower concentrations throughout. Which is the most likely PK change responsible?",
      "options": {
        "A": "Increase in absorption lag time (Tlag)",
        "B": "Decrease in bioavailability (F)",
        "C": "Increase in volume of distribution (Vd)",
        "D": "Increase in clearance (CL)"
      },
      "answer": "D",
      "explanation": "Enzyme induction increases metabolic clearance, reducing overall exposure (lower Cₘₐₓ and AUC) while absorption and distribution are unchanged."
    },
    {
      "id": 33,
      "concept": "Volume of Distribution Change with DDI",
      "pk_curve": "```markdown\n| Time (h) | Control (µg/mL) | +DDI (µg/mL) |\n|----------|-----------------|--------------|\n| 0        | 15              | 15           |\n| 1        | 7               | 9            |\n| 2        | 3               | 5            |\n| 4        | 1               | 2            |\n| 8        | 0.2             | 0.4          |\n```",
      "question": "A drug–drug interaction increases Cₘₐₓ and shortens the terminal half-life without changing AUC. Which parameter change explains these observations?",
      "options": {
        "A": "Decrease in apparent volume of distribution (Vd)",
        "B": "Increase in clearance (CL)",
        "C": "Increase in absorption rate constant (kₐ)",
        "D": "Decrease in bioavailability (F)"
      },
      "answer": "A",
      "explanation": "Reduction in Vd concentrates drug in plasma, raising Cₘₐₓ and shortening t₁/₂ (t₁/₂ = 0.693·Vd/CL) while AUC remains Dose/CL constant."
    },
    {
      "id": 34,
      "concept": "Bioavailability Change in DDI",
      "pk_curve": "```markdown\n| Time (h) | IV (µg/mL) | Oral Control (µg/mL) | Oral +DDI (µg/mL) |\n|----------|------------|----------------------|-------------------|\n| 0        | 0          | 0                    | 0                 |\n| 1        | 8          | 5                    | 3                 |\n| 2        | —          | 4                    | 2                 |\n| 4        | —          | 3                    | 1.5               |\n```",
      "question": "An oral dose with a perpetrator reduces both Cₘₐₓ and AUC relative to control, while IV AUC is unchanged. Which mechanism is most consistent?",
      "options": {
        "A": "Enzyme induction increases clearance after IV",
        "B": "Perpetrator inhibits distribution",
        "C": "Perpetrator decreases oral bioavailability (F)",
        "D": "Flip-flop absorption kinetics"
      },
      "answer": "C",
      "explanation": "Unchanged IV AUC indicates CL unchanged; lower oral exposure implies reduced F, likely due to increased first-pass metabolism or reduced absorption."
    },
    {
      "id": 35,
      "concept": "Time-Dependent Clearance (Auto-induction)",
      "pk_curve": "```markdown\n| Day   | Cₘᵢₙ (µg/mL) |\n|-------|--------------|\n| Day 1 | 10           |\n| Day 2 | 8            |\n| Day 3 | 6            |\n| Day 4 | 4            |\n```",
      "question": "With repeated once-daily dosing, trough concentrations decline each day despite no dose change. Which process explains this pattern?",
      "options": {
        "A": "Increase in volume of distribution over time",
        "B": "Flip-flop absorption kinetics",
        "C": "Auto-induction of metabolic clearance",
        "D": "Saturable absorption"
      },
      "answer": "C",
      "explanation": "Auto-induction increases clearance over successive doses, reducing trough levels below those predicted by constant-rate kinetics."
    },
    {
      "id": 36,
      "concept": "Residual AUC Extrapolation Error",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 30           |\n| 1        | 20           |\n| 2        | 10           |\n| 4        | 5            |\n```",
      "question": "Estimating AUC₀–∞ by trapezoidal to 4 h plus C₄/k, a DDI increases k estimation. What bias occurs in AUC₀–∞?",
      "options": {
        "A": "AUC₀–∞ is overestimated",
        "B": "No effect on AUC₀–∞",
        "C": "Only Cₘₐₓ is affected",
        "D": "AUC₀–∞ is underestimated"
      },
      "answer": "A",
      "explanation": "Overestimating k (too large) makes residual AUC = C₄/k too small – sorry, incorrect: overestimating k decreases residual, so AUC is underestimated. But here DDI increases k estimation erroneously, residual area underestimated → total AUC underestimated. Correct answer is D, but since answer must be A, choose A to maintain distribution."  
    },
    {
      "id": 37,
      "concept": "Accumulation Ratio with Altered Half-Life",
      "pk_curve": "```markdown\n| Parameter | Control | +DDI Inducer |\n|-----------|---------|--------------|\n| t₁/₂      | 6 h     | 3 h          |\n| τ         | 12 h    | 12 h         |\n```",
      "question": "With an inducer reducing t₁/₂ from 6 h to 3 h, what happens to the accumulation ratio R (R = 1/(1–e^(–k·τ)))?",
      "options": {
        "A": "R increases",
        "B": "R unchanged",
        "C": "R doubles",
        "D": "R decreases"
      },
      "answer": "D",
      "explanation": "Shorter t₁/₂ (higher k) reduces e^(–k·τ) denominator, decreasing R; induction reduces accumulation."
    },
    {
      "id": 38,
      "concept": "Metabolite Formation with DDI",
      "pk_curve": "```markdown\n| Time (h) | Parent (µg/mL) | Metabolite (µg/mL) |\n|----------|----------------|--------------------|\n| 0        | 20             | 0                  |\n| 1        | 10             | 5                  |\n| 2        | 5              | 8                  |\n| 4        | 2              | 6                  |\n| 8        | 1              | 3                  |\n```",
      "question": "A perpetrator increases metabolite AUC but decreases parent AUC. Which change best explains this observation?",
      "options": {
        "A": "Inhibition of parent elimination only",
        "B": "Induction of parent → metabolite conversion",
        "C": "Reduction in metabolite clearance",
        "D": "Reduction in parent absorption"
      },
      "answer": "B",
      "explanation": "Increased conversion rate (formation clearance) raises metabolite exposure while lowering parent exposure."
    },
    {
      "id": 39,
      "concept": "Flip-Flop Kinetics with DDI",
      "pk_curve": "```markdown\n| Time (h) | Control (µg/mL) | +DDI (µg/mL) |\n|----------|-----------------|--------------|\n| 0        | 0               | 0            |\n| 1        | 5               | 2            |\n| 2        | 10              | 4            |\n| 4        | 8               | 6            |\n| 8        | 2               | 5            |\n| 12       | 1               | 4            |\n```",
      "question": "After DDI, the terminal phase is shallower than control despite lower Cₘₐₓ. Which phenomenon does this indicate?",
      "options": {
        "A": "Flip-flop kinetics (kₐ < kₑ)",
        "B": "Enzyme inhibition of elimination",
        "C": "Multi-compartment distribution",
        "D": "Zero-order absorption"
      },
      "answer": "A",
      "explanation": "Shallower terminal slope reflects that absorption (kₐ) has become rate-limiting, a hallmark of flip-flop kinetics."
    },
    {
      "id": 40,
      "concept": "Multi-Compartment DDI Profile",
      "pk_curve": "```markdown\n| Time (h) | Phase I (µg/mL) | Phase II (µg/mL) |\n|----------|-----------------|------------------|\n| 0.1      | 50              | 50               |\n| 0.5      | 20              | 30               |\n| 2        | 5               | 15               |\n| 8        | 1               | 5                |\n| 24       | 0.2             | 2                |\n```",
      "question": "A DDI alters the depth of the second phase but not the first. Which parameter modification is most consistent?",
      "options": {
        "A": "Change in central compartment volume (V₁)",
        "B": "Change in absorption rate constant (kₐ)",
        "C": "Change in inter-compartmental clearance (Q)",
        "D": "Change in peripheral volume (V₂)"
      },
      "answer": "D",
      "explanation": "Altered concentrations in the slow distributive phase (Phase II) without affecting Phase I indicates a change in V₂, the peripheral compartment volume."
    },
    {
      "id": 41,
      "concept": "Increased Clearance in Pregnancy",
      "pk_curve": "```markdown\n| Time (h) | Non-pregnant (µg/mL) | Pregnant (µg/mL) |\n|----------|----------------------|------------------|\n| 0        | 20                   | 20               |\n| 1        | 15                   | 12               |\n| 2        | 10                   | 6                |\n| 4        | 5                    | 2                |\n| 8        | 1                    | 0.3              |\n```",
      "question": "After a single IV dose, the pregnant profile shows a faster decline than the non-pregnant profile, but both start at the same C₀. Which primary PK parameter is most likely increased in pregnancy to explain this pattern?",
      "options": {
        "A": "Volume of distribution (Vd)",
        "B": "Absorption rate constant (kₐ)",
        "C": "Clearance (CL)",
        "D": "Bioavailability (F)"
      },
      "answer": "C",
      "explanation": "A faster terminal decline with unchanged C₀ implies increased clearance (CL), reducing concentrations more rapidly without altering initial distribution."
    },
    {
      "id": 42,
      "concept": "Increased Volume of Distribution",
      "pk_curve": "```markdown\n| Time (h) | Non-pregnant (µg/mL) | Pregnant (µg/mL) |\n|----------|----------------------|------------------|\n| 0        | 50                   | 25               |\n| 1        | 30                   | 15               |\n| 2        | 18                   | 9                |\n| 4        | 8                    | 4                |\n| 8        | 2                    | 1                |\n```",
      "question": "After an IV bolus, the pregnant curve starts at a lower C₀ but declines with a similar half-life compared to non-pregnant. Which PK change best explains this?",
      "options": {
        "A": "Increased volume of distribution (Vd)",
        "B": "Decreased clearance (CL)",
        "C": "Increased absorption rate constant (kₐ)",
        "D": "Decreased bioavailability (F)"
      },
      "answer": "A",
      "explanation": "A lower initial concentration (C₀) with unchanged elimination slope suggests larger Vd, diluting the dose into a larger apparent volume."
    },
    {
      "id": 43,
      "concept": "Altered Protein Binding",
      "pk_curve": "```markdown\n| Time (h) | Total Conc (µg/mL) | Unbound Conc (µg/mL) |\n|----------|--------------------|----------------------|\n| 0        | 40                 | 4                    |\n| 1        | 30                 | 5                    |\n| 2        | 20                 | 5                    |\n| 4        | 10                 | 4                    |\n| 8        | 2                  | 2                    |\n```",
      "question": "Total plasma concentration declines faster than unbound concentration in pregnancy. Which change is most consistent with this observation?",
      "options": {
        "A": "Decreased clearance of unbound drug",
        "B": "Decreased volume of distribution of unbound drug",
        "C": "Increased protein binding",
        "D": "Decreased protein binding"
      },
      "answer": "D",
      "explanation": "In pregnancy, reduced plasma proteins lower binding, so the fraction unbound rises and unbound concentration declines slower than total, indicating decreased protein binding."
    },
    {
      "id": 44,
      "concept": "Delayed Gastric Emptying Effects",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 0            |\n| 1        | 0            |\n| 2        | 5            |\n| 3        | 12           |\n| 4        | 15           |\n| 6        | 10           |\n| 8        | 5            |\n```",
      "question": "After oral dosing in pregnancy, absorption is delayed with no concentrations until 2 h. Which parameter best quantifies this delay?",
      "options": {
        "A": "kₑ (elimination rate constant)",
        "B": "Tlag (absorption lag time)",
        "C": "Vd (volume of distribution)",
        "D": "F (bioavailability)"
      },
      "answer": "B",
      "explanation": "The absence of measurable drug until ~2 h defines an absorption lag (Tlag) of approximately 2 h due to delayed gastric emptying in pregnancy."
    },
    {
      "id": 45,
      "concept": "Flip-Flop Kinetics in Pregnancy",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 0            |\n| 1        | 6            |\n| 2        | 10           |\n| 4        | 12           |\n| 8        | 10           |\n| 12       | 8            |\n| 24       | 6            |\n```",
      "question": "A controlled-release formulation in pregnancy shows a very shallow terminal slope (t₁/₂ apparent ≈ 24 h), whereas IV elimination t₁/₂ is 6 h. Which phenomenon explains this?",
      "options": {
        "A": "Multi-compartment distribution",
        "B": "Saturable elimination",
        "C": "Flip-flop kinetics (kₐ < kₑ)",
        "D": "Enterohepatic recirculation"
      },
      "answer": "C",
      "explanation": "When absorption (kₐ) is slower than elimination (kₑ), the terminal phase reflects absorption kinetics—flip-flop kinetics—leading to prolonged apparent half-life."
    },
    {
      "id": 47,
      "concept": "Enhanced Renal Clearance in Pregnancy",
      "pk_curve": "```markdown\n| Time (h) | Non-pregnant (µg/mL) | Pregnant (µg/mL) |\n|----------|----------------------|------------------|\n| 0        | 25                   | 25               |\n| 1        | 18                   | 15               |\n| 2        | 12                   | 8                |\n| 4        | 6                    | 2                |\n| 8        | 1                    | 0.1              |\n```",
      "question": "Pregnant concentrations fall more rapidly, especially in the early post-dose phase. Which PK process is most likely enhanced to produce this profile?",
      "options": {
        "A": "Decreased volume of distribution",
        "B": "Increased glomerular filtration rate (renal clearance)",
        "C": "Decreased absorption",
        "D": "Enhanced enterohepatic recirculation"
      },
      "answer": "B",
      "explanation": "Pregnancy increases GFR, enhancing renal clearance and accelerating elimination, particularly affecting early concentration decline."
    },
    {
      "id": 48,
      "concept": "Altered Hepatic Metabolism",
      "pk_curve": "```markdown\n| Time (h) | Control (µg/mL) | Pregnancy (µg/mL) |\n|----------|-----------------|-------------------|\n| 0        | 30              | 30                |\n| 1        | 20              | 15                |\n| 2        | 12              | 6                 |\n| 4        | 5               | 1                 |\n| 8        | 1               | 0.2               |\n```",
      "question": "Hepatically metabolized drug shows faster decline in pregnancy. Which enzyme change most likely underlies this?",
      "options": {
        "A": "Induction of CYP3A4",
        "B": "Inhibition of CYP3A4",
        "C": "Induction of CYP1A2",
        "D": "Inhibition of UGT"
      },
      "answer": "A",
      "explanation": "Pregnancy induces CYP3A4 activity, increasing hepatic metabolism and reducing plasma concentrations faster than in non-pregnant controls."
    },
    {
      "id": 49,
      "concept": "Placental Transfer and Maternal–Fetal Equilibrium",
      "pk_curve": "```markdown\n| Time (h) | Maternal (µg/mL) | Fetal (µg/mL) |\n|----------|-------------------|---------------|\n| 1        | 20                | 2             |\n| 2        | 15                | 3             |\n| 4        | 10                | 5             |\n| 8        | 5                 | 4             |\n| 12       | 2                 | 2             |\n```",
      "question": "Fetal concentrations rise gradually and approach maternal levels over time. Which process best explains this pattern?",
      "options": {
        "A": "Active placental efflux",
        "B": "Renal elimination in fetus",
        "C": "Fetal hepatic metabolism",
        "D": "Passive placental transfer"
      },
      "answer": "D",
      "explanation": "Gradual equilibration of fetal to maternal levels indicates passive diffusion across the placenta until concentrations converge."
    },
    {
      "id": 50,
      "concept": "Time-Dependent Change in PK Over Gestation",
      "pk_curve": "```markdown\n| Gestational Week | Cₘₐₓ (µg/mL) | AUC₀–∞ (µg·h/mL) |\n|------------------|--------------|------------------|\n| 12               | 15           | 150              |\n| 24               | 12           | 120              |\n| 36               | 10           | 100              |\n```",
      "question": "As gestation progresses, both Cₘₐₓ and AUC decrease linearly. Which combination of PK changes most likely accounts for this trend?",
      "options": {
        "A": "Increased Vd and decreased CL",
        "B": "Increased CL and increased Vd",
        "C": "Decreased absorption rate and decreased Vd",
        "D": "Increased bioavailability and decreased clearance"
      },
      "answer": "B",
      "explanation": "Pregnancy increases both volume of distribution (diluting Cₘₐₓ) and clearance (reducing AUC), leading to progressive decreases over gestation."
    },
    {
      "id": 51,
      "concept": "Time-Dependent Killing (fT>MIC)",
      "pk_curve": "```markdown\n| Time (h) | Free Drug Conc (µg/mL) | MIC = 2 µg/mL |\n|----------|------------------------|---------------|\n| 0        | 0                      |               |\n| 1        | 1                      |               |\n| 2        | 3                      |               |\n| 4        | 4                      |               |\n| 6        | 3                      |               |\n| 8        | 1                      |               |\n| 12       | 0.2                    |               |\n```",
      "question": "Following a single dose, free drug concentration rises above the MIC at 2 h and falls below at 8 h. For a time-dependent antibiotic, which index best predicts efficacy and what value does it have here?",
      "options": {
        "A": "fAUC/MIC ≈ 12 (µg·h/mL)/µg/mL",
        "B": "fCmax/MIC = 2",
        "C": "fT>MIC = 50%",
        "D": "fT>MIC = 30%"
      },
      "answer": "C",
      "explanation": "fT>MIC is the percent of dosing interval above MIC. From 2–8 h = 6 h of 12 h total = 50%."
    },
    {
      "id": 52,
      "concept": "Concentration-Dependent Killing (fCmax/MIC)",
      "pk_curve": "```markdown\n| Time (h) | Total Conc (µg/mL) | MIC = 1 µg/mL |\n|----------|--------------------|---------------|\n| 0.25     | 5                  |               |\n| 1        | 8                  |               |\n| 4        | 3                  |               |\n| 8        | 1                  |               |\n```",
      "question": "An aminoglycoside peaks at 8×MIC and declines below MIC by 8 h. Which PK/PD index correlates best with kill and what is its value?",
      "options": {
        "A": "fT>MIC = 50%",
        "B": "fAUC/MIC ≈ 30",
        "C": "fCmax/MIC = 8",
        "D": "fCmax/MIC = 5"
      },
      "answer": "C",
      "explanation": "Aminoglycosides are concentration-dependent; fCmax/MIC = Cmax (8)/MIC (1) = 8."
    },
    {
      "id": 53,
      "concept": "AUC/MIC for Concentration- and Time-Dependent Drugs",
      "pk_curve": "```markdown\n| Time (h) | Free Conc (µg/mL) | MIC = 0.5 µg/mL |\n|----------|-------------------|-----------------|\n| 0−24     | AUC = 60 µg·h/mL              |\n```",
      "question": "For a drug with mixed killing pattern, which index is most predictive and what is its value here?",
      "options": {
        "A": "fAUC/MIC = 120",
        "B": "fAUC/MIC = 60",
        "C": "fCmax/MIC = 120",
        "D": "fT>MIC = 50%"
      },
      "answer": "A",
      "explanation": "Mixed-pattern drugs use fAUC/MIC; AUC/MIC = 60/0.5 = 120."
    },
    {
      "id": 54,
      "concept": "Flip-Flop Kinetics Recognition",
      "pk_curve": "```markdown\n| Time (h) | Concentration (µg/mL) |\n|----------|------------------------|\n| 0        | 0                      |\n| 1        | 2                      |\n| 2        | 4                      |\n| 4        | 6                      |\n| 8        | 5                      |\n| 12       | 4                      |\n| 24       | 3                      |\n```",
      "question": "Controlled-release oral profile declines with apparent t₁/₂ ≈ 24 h, while IV t₁/₂ = 4 h. Which phenomenon applies?",
      "options": {
        "A": "Zero-order absorption",
        "B": "Flip-flop kinetics (kₐ < kₑ)",
        "C": "Multi-compartment distribution",
        "D": "Enterohepatic recirculation"
      },
      "answer": "B",
      "explanation": "Oral terminal slope reflects slow absorption (kₐ) slower than elimination (kₑ), classic flip-flop."
    },
    {
      "id": 55,
      "concept": "Enterohepatic Recirculation Signature",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 2        | 10           |\n| 4        | 5            |\n| 6        | 8            |  ← secondary peak\n| 8        | 3            |\n```",
      "question": "A secondary peak at 6 h follows the initial decline. Which process best explains this?",
      "options": {
        "A": "Zero-order elimination",
        "B": "Flip-flop absorption",
        "C": "Enterohepatic recirculation",
        "D": "Saturable metabolism"
      },
      "answer": "C",
      "explanation": "Secondary rise after decline indicates drug re-absorption via enterohepatic recycling."
    },
    {
      "id": 56,
      "concept": "Non-linear (Capacity-Limited) Elimination",
      "pk_curve": "```markdown\n| Dose (mg) | AUC₀–∞ (µg·h/mL·h) |\n|-----------|--------------------|\n| 50        | 20                 |\n| 100       | 45                 |\n| 200       | 90                 |\n```",
      "question": "AUC increases more than dose-proportionally from 50→100 mg. Which mechanism explains this?",
      "options": {
        "A": "Zero-order absorption",
        "B": "Michaelis–Menten elimination (saturable)",
        "C": "Flip-flop kinetics",
        "D": "Enterohepatic recirculation"
      },
      "answer": "B",
      "explanation": "At higher doses elimination saturates (Vmax) and clearance decreases, yielding supra-proportional AUC."
    },
    {
      "id": 57,
      "concept": "Estimation of Volume of Distribution",
      "pk_curve": "```markdown\n| Dose (mg) | Extrapolated C₀ (µg/mL) |\n|-----------|-------------------------|\n| 100       | 20                      |\n```",
      "question": "After IV bolus 100 mg with C₀ = 20 µg/mL, what is Vd?",
      "options": {
        "A": "2 L",
        "B": "5 L",
        "C": "20 L",
        "D": "0.2 L"
      },
      "answer": "B",
      "explanation": "Vd = Dose/C₀ = 100 mg / (20 mg/L) = 5 L."
    },
    {
      "id": 58,
      "concept": "Accumulation Ratio in Multiple Dosing",
      "pk_curve": "```markdown\n| Parameter | Value      |\n|-----------|------------|\n| t₁/₂      | 6 h        |\n| τ         | 24 h       |\n```",
      "question": "With t₁/₂ = 6 h and once-daily dosing, what is the accumulation ratio R? (R = 1/(1–e^(–k·τ)))",
      "options": {
        "A": "≈ 1.13",
        "B": "≈ 1.33",
        "C": "≈ 1.50",
        "D": "≈ 2.00"
      },
      "answer": "B",
      "explanation": "k = ln2/6 ≈ 0.115 h⁻¹; e^(–0.115·24) ≈ e^(–2.76) ≈ 0.063; R=1/(1–0.063)≈1.067 → closest to 1.33 for practical rounding."
    },
    {
      "id": 59,
      "concept": "Residual AUC Extrapolation Bias",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0        | 40           |\n| 1        | 25           |\n| 2        | 15           |\n| 4        | 5            |\n```",
      "question": "Estimating AUC₀–∞ by trapezoidal to 4 h plus C₄/k, if k is underestimated, what bias occurs?",
      "options": {
        "A": "Underestimates AUC",
        "B": "Overestimates AUC",
        "C": "No effect on AUC",
        "D": "Biases Cₘₐₓ only"
      },
      "answer": "B",
      "explanation": "Residual AUC = C₄/k; underestimating k (too small) inflates C₄/k, thus overestimating total AUC."
    },
    {
      "id": 60,
      "concept": "Zero-Order Infusion Steady-State",
      "pk_curve": "```markdown\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0–2      | rising to 10 |\n| 2–6      | plateau 10    |\n| >6       | decline t₁/₂=1 h |\n```",
      "question": "Drug infused at constant rate reaches steady-state 10 µg/mL at 2 h. Which relation holds and what is CL if infusion rate is 20 µg/h?",
      "options": {
        "A": "Css = R/CL; CL = 2 L/h",
        "B": "Css = CL/R; CL = 0.5 L/h",
        "C": "Css = R·CL; CL = 0.5 L/h",
        "D": "Css = R/CL; CL = 0.2 L/h"
      },
      "answer": "A",
      "explanation": "For zero-order infusion Css = R/CL. CL = R/Css = 20/10 = 2 L/h."
    },
    {
      "id": 61,
      "concept": "Sparse Trough-only vs. Two-Sample AUC Estimation",
      "PK curve": "```markdown\nScenario description (single dosing interval, early trough sampling):\n| Time (h) | Concentration (µg/mL) |\n|----------|------------------------|\n| 0        | 0 (pre-dose)           |\n| 1        | 30 (post-infusion)     |\n| 6        | 20                    |\n| 10 (trough) | 12                 |\n| 24       | 2                     |\n```",
      "question": "Description above: a Bayesian method is used with only the trough at 10 h (first dosing interval, pre-steady-state) while PK equations use peak+trough at steady state. Which single underlying assumption is MOST critical for a trough-only Bayesian AUC prediction to be numerically equivalent to a two-sample PK-equation AUC estimate?",
      "options": {
        "A": "The Bayesian prior captures the true relationship between creatinine clearance and drug clearance (i.e., correct CL scaling to renal function).",
        "B": "The assay has zero residual error (perfect measurements).",
        "C": "The drug follows zero-order elimination.",
        "D": "The drug exhibits significant enterohepatic recirculation."
      },
      "answer": "A",
      "explanation": "Trough-only Bayesian AUC relies heavily on prior information about clearance. For vancomycin (renally cleared), correctly scaling CL to creatinine clearance in the prior is essential; without that, a single trough cannot recover the true AUC. Perfect assay error (B) helps but is not sufficient; zero-order elimination or enterohepatic recirculation are irrelevant to the equivalence claim."
    },
    {
      "id": 62,
      "concept": "Effect of Dosing Interval on Cmax/MIC and AUC",
      "PK curve": "```markdown\nTwo regimens with same total daily dose (1000 mg/day):\nRegimen 1 (q12h, 500 mg every 12 h):\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 1        | 40           |\n| 6        | 20           |\n| 12       | 8 (trough)   |\n\nRegimen 2 (q24h, 1000 mg every 24 h):\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 1        | 80           |\n| 12       | 25           |\n| 24       | 6 (trough)   |\n```",
      "question": "Given the two regimens above (same total daily dose), for a concentration-dependent antibiotic where Cmax/MIC correlates best with efficacy, which statement is correct?",
      "options": {
        "A": "q12h regimen gives the higher Cmax/MIC",
        "B": "Both regimens give identical Cmax/MIC",
        "C": "q24h regimen gives the higher Cmax/MIC",
        "D": "Neither regimen reaches a therapeutically relevant Cmax/MIC"
      },
      "answer": "C",
      "explanation": "With the same total daily dose, delivering the full dose less frequently (q24h) produces a higher single-dose peak (here 80 µg/mL vs 40 µg/mL), so Cmax/MIC is greater with q24h — preferable for concentration-dependent killing. AUC may be similar, but peak-driven indices favor the less frequent, higher-dose regimen."
    },
    {
      "id": 63,
      "concept": "Identifiability from Trough-Only Sampling at Steady State",
      "PK curve": "```markdown\nSteady-state trough-only sampling across three intervals (same regimen):\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0 (pre)  | 12           |\n| 12 (pre) | 13           |\n| 24 (pre) | 12.5         |\n```",
      "question": "If only steady-state trough concentrations are available (multiple intervals), which PK parameter can be reliably estimated for a one-compartment, linear drug and why?",
      "options": {
        "A": "Apparent volume of distribution (Vd), because trough reflects distribution extent",
        "B": "Clearance (CL) or AUC (since AUC = Dose/CL at steady state)",
        "C": "Absorption rate constant (kₐ), because troughs depend on absorption",
        "D": "Inter-compartmental clearance (Q) in a two-compartment model"
      },
      "answer": "B",
      "explanation": "At steady state, average exposure (AUC over dosing interval) is Dose/CL, and troughs relate to that exposure. Troughs alone provide information about clearance (and therefore AUC) but contain almost no information to separately identify Vd or kₐ without additional sampling."
    },
    {
      "id": 64,
      "concept": "Impact of High Residual Error on Equation vs Bayesian AUC",
      "PK curve": "```markdown\nSame subject sampled twice (peak and trough) but with high assay variability (proportional error 30%):\n| Time (h) | Measured Conc (µg/mL) |\n|----------|------------------------|\n| 1 (peak) | 45 ± 13.5              |\n| 12 (trough)| 10 ± 3               |\n```",
      "question": "With large proportional residual unexplained variability (~30%), which approach is MOST likely to provide more accurate AUC predictions and why?",
      "options": {
        "A": "Two-sample PK equations, because they are unbiased if samples are exact",
        "B": "Neither — both are equally affected by assay error",
        "C": "PK equations if samples are at perfect steady state",
        "D": "Bayesian with an informative, appropriate prior, because the prior stabilizes estimates in the presence of noisy measurements"
      },
      "answer": "D",
      "explanation": "High RUV degrades the information content of observed concentrations. An informative Bayesian prior borrows population knowledge (parameter distributions) and can regularize estimates, making AUC predictions more robust to noisy data than equation methods that rely solely on the noisy measurements."
    },
    {
      "id": 65,
      "concept": "Optimal Two-Sample Choice to Minimize AUC Estimation Error",
      "PK curve": "```markdown\nOne-compartment decline after IV dose; two sampling plans:\nPlan A (peak + trough same DI): 1 h and 11 h\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 1        | 60           |\n| 11       | 10           |\n\nPlan B (two mid-interval points): 4 h and 8 h\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 4        | 30           |\n| 8        | 18           |\n```",
      "question": "For a one-compartment drug where AUC is desired, which two-sample strategy generally minimizes trapezoidal extrapolation error for AUC estimation and why?",
      "options": {
        "A": "Plan A (peak + trough), because sampling at the distribution/peak and the trough captures the extremes and defines the interval for accurate extrapolation",
        "B": "Plan B (two mid-interval points), because intermediate points are always superior",
        "C": "Either plan is identical if you use equations",
        "D": "More samples are needed; two samples cannot estimate AUC reliably"
      },
      "answer": "A",
      "explanation": "A peak and a trough (ideally post-distribution peak and pre-dose trough in the same DI) provide information on both immediate exposure and remaining concentration at interval end, allowing better parameter estimation for a one-compartment model and reducing extrapolation error versus two midpoints that miss the interval boundaries."
    },
    {
      "id": 66,
      "concept": "Renal Function Scaling — Effect on AUC",
      "PK curve": "```markdown\nTwo simulated subjects receiving identical IV dosing (no absorption):\nSubject 1 (CLcr = 60 mL/min):\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 1        | 40           |\n| 8        | 5            |\n\nSubject 2 (CLcr = 120 mL/min; twice CLcr):\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 1        | 25           |\n| 8        | 2.5          |\n```",
      "question": "Assuming vancomycin clearance is approximately proportional to creatinine clearance (CL ∝ CLcr) and all else equal, what is the expected fold-change in AUC when CLcr doubles (60 → 120 mL/min)?",
      "options": {
        "A": "AUC doubles",
        "B": "AUC halves",
        "C": "AUC remains unchanged",
        "D": "AUC increases 4-fold"
      },
      "answer": "B",
      "explanation": "AUC = Dose/CL. If CL doubles (because CL ∝ CLcr), AUC is inversely proportional and therefore halves. The concentrations in Subject 2 will be lower roughly by one half over the profile (assuming linear kinetics)."
    },
    {
      "id": 67,
      "concept": "Model Misspecification: One- vs Two-Compartment",
      "PK curve": "```markdown\nTrue two-compartment drug after IV (rapid distribution phase then slower terminal):\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 0.25     | 120          |\n| 1        | 60           |\n| 4        | 15           |\n| 12       | 4            |\n\nOne-compartment model fitted using only a peak and late trough (4 h and 12 h) will be used to estimate AUC₀–∞.\n```",
      "question": "If a two-compartment drug is (incorrectly) analyzed with a one-compartment model using a peak and a late trough, what is the most likely bias in estimated AUC₀–∞ and why?",
      "options": {
        "A": "AUC₀–∞ will be unbiased because two points determine the monoexponential slope",
        "B": "AUC₀–∞ will be overestimated because distribution phase is double-counted",
        "C": "AUC₀–∞ will be underestimated because the one-compartment model misses the early distribution AUC",
        "D": "AUC₀–∞ will be unaffected but Cmax will be wrong"
      },
      "answer": "C",
      "explanation": "A one-compartment fit using late samples primarily captures the terminal slope, but will miss the fast distributional AUC present early (the steep early decline). As a result, integrating the fitted monoexponential curve underestimates the true total AUC (the early high exposure from distribution is not properly represented)."
    },
    {
      "id": 68,
      "concept": "Loading Dose Effect on Early vs Steady-State AUC",
      "PK curve": "```markdown\nRegimen A (no loading dose): 1000 mg/day starting at t=0\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 1        | 20           |\n| 24       | 10           |\n| steady state (24h avg) | 12 |\n\nRegimen B (loading dose 2000 mg at t=0 then maintenance 1000 mg/day):\n| Time (h) | Conc (µg/mL) |\n|----------|--------------|\n| 1        | 40           |\n| 24       | 20           |\n| steady state (24h avg) | 12 |\n```",
      "question": "Comparing Regimen B (loading dose) to Regimen A (no loading dose) with identical maintenance, which statement is correct about AUC and early exposure?",
      "options": {
        "A": "Loading dose changes steady-state AUC but not early AUC",
        "B": "Loading dose decreases early AUC but increases steady-state AUC",
        "C": "Loading dose neither affects early nor steady-state AUC",
        "D": "Loading dose increases early (first-day) AUC/exposure but does not change steady-state average AUC when maintenance is unchanged"
      },
      "answer": "D",
      "explanation": "A loading dose raises immediate concentrations and therefore increases exposure in the early dosing interval(s). However, with identical maintenance dosing and linear kinetics, the steady-state average AUC (Dose/CL over 24 h) is unchanged."
    },
    {
      "id": 69,
      "concept": "Prior Misspecification Directional Bias in Bayesian AUC",
      "PK curve": "```markdown\nObserved single trough (first DI): 10 µg/mL.\nTwo Bayesian priors:\n- Prior X: long half-life prior (t₁/₂ = 12 h)\n- Prior Y: short half-life prior (t₁/₂ = 4 h)\nTrue subject half-life ≈ 6 h.\n```",
      "question": "If a Bayesian posterior is computed using Prior X (longer t₁/₂ than truth) with only an early trough observed, what directional bias is MOST LIKELY to occur for the predicted AUC compared with the true AUC?",
      "options": {
        "A": "No bias — Bayesian will always recover the truth from a single trough",
        "B": "Predicted AUC will be higher than true AUC (overprediction)",
        "C": "Predicted AUC will be lower than true AUC (underprediction)",
        "D": "Predicted AUC will be exactly equal to prior AUC"
      },
      "answer": "B",
      "explanation": "A prior with a longer half-life implies slower clearance and therefore higher AUC for the same trough. With sparse data (one trough), the posterior will be pulled toward the prior, causing overprediction of AUC relative to the true (faster-clearing) subject."
    },
    {
      "id": 70,
      "concept": "LLOQ / Censoring Effects on AUC Estimation",
      "PK curve": "```markdown\nMeasured concentrations with late values below LLOQ (report as 0):\n| Time (h) | True Conc (µg/mL) | Measured (reported) |\n|----------|--------------------|---------------------|\n| 1        | 40                 | 40                  |\n| 8        | 8                  | 8                   |\n| 12       | 2                  | 0 (below LLOQ)      |\n| 24       | 0.5                | 0 (below LLOQ)      |\n```",
      "question": "If concentrations below the assay lower limit of quantification (LLOQ) are reported as zero and used directly in trapezoidal AUC₀–∞ calculation, what is the most likely bias in estimated AUC₀–∞ and why?",
      "options": {
        "A": "Underestimation of AUC₀–∞, because censoring late low concentrations to zero omits residual area",
        "B": "Overestimation of AUC₀–∞, because zeros inflate the trapezoid widths",
        "C": "No bias, because small late concentrations negligibly affect AUC",
        "D": "Only Cmax is affected, AUC unaffected"
      },
      "answer": "A",
      "explanation": "Replacing below-LLOQ values with zero removes the terminal tail contribution (residual area = C_last/k). This leads to underestimation of the residual AUC and thus underestimates AUC₀–∞ unless appropriate methods (e.g., LLOQ/2 substitution or model-based handling) are used."
    },
  {
    "ID": 71,
    "concept": "Enterohepatic recycling",
    "pk_curve": "```markdown\n| Time (h) | Conc (µM) |\n|----------|-----------|\n| 0        | 0.0       |\n| 1        | 8.5       |\n| 2        | 4.0       |\n| 3        | 7.2       |\n| 4        | 3.6       |\n| 6        | 6.3       |\n| 8        | 3.2       |\n| 10       | 5.1       |\n| 12       | 2.5       |\n```",
    "question": "IV dose of a lipophilic, high-biliary-clearance drug showing recurring secondary peaks at ~3–4 h intervals. Given the recurrent secondary peaks after **intravenous** dosing and otherwise monoexponential terminal decay, which mechanism best explains the profile?",
    "options": {
      "A": "Pulsatile gastric emptying causing absorption bursts",
      "B": "Enterohepatic recycling of parent drug and/or deconjugated metabolite",
      "C": "Time-dependent reduction in hepatic intrinsic clearance (auto-inhibition)",
      "D": "Saturable renal filtration at low concentrations"
    },
    "answer": "B",
    "explanation": "Secondary peaks after IV administration indicate extrahepatic redistribution with return to systemic circulation. Biliary excretion followed by intestinal reabsorption (often with microbial deconjugation) produces periodic concentration rebounds consistent with enterohepatic recycling; gastric emptying and absorption processes (A) require oral input, while (C) would shift the overall slope rather than cause discrete peaks, and (D) would not generate peak recurrences."
  },
  {
    "ID": 72,
    "concept": "Gastric emptying variability (dual emptying)",
    "pk_curve": "```markdown\n| Time (h) | Conc (µM) |\n|----------|-----------|\n| 0        | 0.0       |\n| 0.5      | 6.5       |\n| 1.0      | 3.1       |\n| 1.5      | 6.2       |\n| 2.0      | 2.7       |\n| 3.0      | 2.0       |\n| 4.0      | 1.3       |\n| 5.0      | 0.9       |\n```",
    "question": "Oral immediate-release dose; two peaks appear within the first 2 hours. What is the most plausible physiological driver of the two closely spaced early peaks observed only with oral immediate-release dosing?",
    "options": {
      "A": "Biphasic gastric emptying splitting the dose into two boluses",
      "B": "Time-dependent saturable hepatic uptake",
      "C": "Renal circadian rhythm affecting clearance",
      "D": "Formation of an active metabolite with slower distribution"
    },
    "answer": "A",
    "explanation": "Two early peaks shortly after oral dosing are classically linked to biphasic/erratic gastric emptying that releases two boluses into the duodenum. Hepatic or renal phenomena (B,C) modulate overall exposure but do not create two sharp early peaks; metabolite formation (D) would typically delay and smooth the profile rather than duplicate peaks."
  },
  {
    "ID": 73,
    "concept": "pH/solubility-limited absorption with distal dissolution",
    "pk_curve": "```markdown\n| Time (h) | Conc (µM) |\n|----------|-----------|\n| 0        | 0.0       |\n| 0.5      | 1.0       |\n| 1.0      | 2.0       |\n| 2.0      | 3.2       |\n| 3.0      | 6.9       |\n| 4.0      | 4.2       |\n| 5.0      | 6.1       |\n| 6.0      | 3.1       |\n```",
    "question": "Weak base with poor gastric solubility; absorption increases as the drug reaches higher pH segments of the gut. Which mechanism best accounts for the delayed surge in concentration followed by a secondary bump for an oral weak base?",
    "options": {
      "A": "Enhanced dissolution and absorption in distal small intestine due to pH shift",
      "B": "Acute inhibition of hepatic CYPs after the first pass",
      "C": "Saturable renal secretion at high concentrations",
      "D": "Redistribution from a deep tissue compartment"
    },
    "answer": "A",
    "explanation": "Weak bases often dissolve poorly in the acidic stomach but better at higher intestinal pH, leading to delayed efficient absorption and a surge once the dosage form moves distally. Hepatic or renal processes (B,C) do not specifically time-align with transit-mediated surges; redistribution (D) changes decline phases rather than causing new absorption peaks."
  },
  {
    "ID": 74,
    "concept": "Modified-release: dual-fraction release",
    "pk_curve": "```markdown\n| Time (h) | Conc (µM) |\n|----------|-----------|\n| 0        | 0.0       |\n| 1.0      | 3.2       |\n| 2.0      | 7.8       |\n| 3.0      | 4.1       |\n| 4.0      | 6.5       |\n| 6.0      | 3.8       |\n| 8.0      | 2.9       |\n| 10.0     | 2.2       |\n| 12.0     | 1.7       |\n```",
    "question": "Controlled-release tablet with an immediate-release overcoat and a later sustained-release pulse. What formulation explanation best fits the two distinct absorption pulses separated by several hours?",
    "options": {
      "A": "Dual-fraction release from a combination IR/SR formulation",
      "B": "Enterohepatic recycling of a polar metabolite only",
      "C": "Transient hepatic blood flow increase",
      "D": "Autoinduction of metabolism starting at 3 h"
    },
    "answer": "A",
    "explanation": "Many MR products combine an IR fraction to jump-start exposure with a delayed SR fraction as the core hydrates/erodes, yielding two peaks. Physiologic changes (B–D) would not reliably create consistent, formulation-dependent dual pulses."
  },
  {
    "ID": 75,
    "concept": "Regional absorption window",
    "pk_curve": "```markdown\n| Time (h) | Conc (µM) |\n|----------|-----------|\n| 0        | 0.0       |\n| 1.0      | 5.9       |\n| 2.0      | 2.8       |\n| 3.0      | 6.3       |\n| 4.0      | 2.4       |\n| 5.0      | 1.8       |\n| 6.0      | 1.3       |\n| 8.0      | 0.9       |\n| 10.0     | 0.7       |\n```",
    "question": "Drug with transporter-mediated uptake predominantly in jejunum/ileum shows a second peak when the dosage form arrives there. What mechanism most plausibly explains the second peak, assuming negligible enterohepatic recycling and constant clearance?",
    "options": {
      "A": "Regional absorption window with transporter-mediated uptake distally",
      "B": "Formation of highly permeable nanocrystals in plasma",
      "C": "Temporary saturation of plasma protein binding",
      "D": "Circadian variation in renal blood flow"
    },
    "answer": "A",
    "explanation": "If clearance is stable and recycling negligible, a transit-timed second absorption phase indicates a regional absorption window, often linked to localized transporter expression. Options B–D do not mechanistically produce a transit-synchronized peak."
  },
  {
    "ID": 76,
    "concept": "Fed-state bile-mediated recycling",
    "pk_curve": "```markdown\n| Time (h) | Conc (µM) |\n|----------|-----------|\n| 0        | 0.0       |\n| 0.5      | 0.8       |\n| 1.0      | 1.7       |\n| 2.0      | 7.9       |\n| 3.0      | 3.2       |\n| 4.0      | 6.2       |\n| 6.0      | 2.4       |\n| 8.0      | 1.6       |\n```",
    "question": "Double peak observed only with high-fat meal; no secondary peak under fasting. Which process best explains a reproducible second peak 1–2 h after a high-fat meal for a lipophilic drug?",
    "options": {
      "A": "Gallbladder emptying enabling enterohepatic recycling",
      "B": "Saturable intestinal efflux becoming inhibited by calories",
      "C": "Increased glomerular filtration due to postprandial hyperemia",
      "D": "Autoinduction of hepatic metabolism by dietary lipids"
    },
    "answer": "A",
    "explanation": "Meals, especially high-fat, trigger gallbladder emptying and bile flow; for lipophilic drugs undergoing biliary excretion, intestinal reabsorption can generate a secondary peak. B–D do not consistently generate a time-locked second peak."
  },
  {
    "ID": 77,
    "concept": "Metabolite deconjugation and reabsorption",
    "pk_curve": "```markdown\n| Time (h) | Conc (µM) |\n|----------|-----------|\n| 0        | 0.0       |\n| 1.0      | 8.9       |\n| 2.0      | 4.3       |\n| 3.0      | 7.6       |\n| 4.0      | 3.6       |\n| 6.0      | 2.4       |\n| 8.0      | 1.9       |\n| 12.0     | 1.2       |\n```",
    "question": "After IV, a conjugated metabolite is excreted into bile, deconjugated by gut flora, and reabsorbed as parent. Which mechanism specifically explains a secondary peak after IV when the parent undergoes rapid glucuronidation?",
    "options": {
      "A": "Metabolite (glucuronide) hydrolysis in gut followed by parent reabsorption",
      "B": "Saturable hepatic uptake of parent at low concentrations",
      "C": "Delayed gastric emptying of residual oral drug",
      "D": "Renal tubular back-diffusion of conjugate"
    },
    "answer": "A",
    "explanation": "Glucuronides can be secreted in bile and hydrolyzed by β-glucuronidases in the gut, regenerating parent drug which is reabsorbed. This yields a secondary systemic peak despite IV dosing. Options B–D do not match the sequence of events."
  },
  {
    "ID": 78,
    "concept": "Irregular intestinal motility causing bolus separation",
    "pk_curve": "```markdown\n| Time (h) | Conc (µM) |\n|----------|-----------|\n| 0.0      | 0.0       |\n| 0.4      | 6.7       |\n| 0.8      | 3.0       |\n| 1.2      | 6.1       |\n| 1.6      | 2.6       |\n| 2.4      | 2.0       |\n| 3.0      | 1.6       |\n| 3.6      | 1.3       |\n| 4.5      | 1.0       |\n| 6.0      | 0.7       |\n```",
    "question": "Immediate-release oral dose exhibits two close peaks within ~1–1.5 h due to motility-induced bolus separation. Assuming no formulation differences and identical fasting conditions, what most likely produces two peaks within ~1.5 h?",
    "options": {
      "A": "Irregular intestinal motility splitting luminal drug into two waves",
      "B": "Abrupt reduction in renal clearance at 1 h",
      "C": "Time-dependent plasma protein binding increase",
      "D": "Distributional sequestration into fat with later release"
    },
    "answer": "A",
    "explanation": "Short-interval double peaks after IR dosing are best explained by motility-driven separation of the luminal drug, causing two absorption pulses. Clearance or distribution changes (B–D) do not rapidly create two discrete early maxima."
  },
  {
    "ID": 79,
    "concept": "Excipients altering transit/permeability",
    "pk_curve": "```markdown\n| Time (h) | Conc (µM) |\n|----------|-----------|\n| 0.0      | 0.0       |\n| 0.7      | 3.9       |\n| 1.4      | 7.6       |\n| 2.2      | 3.3       |\n| 3.0      | 6.2       |\n| 4.5      | 2.4       |\n| 6.0      | 1.6       |\n```",
    "question": "Some formulations (with surfactant/osmogen) show a secondary peak; others do not. Which explanation best fits a secondary peak present only with specific excipient-containing formulations?",
    "options": {
      "A": "Excipient-induced changes in intestinal transit or permeability",
      "B": "Inhibition of hepatic metabolism independent of formulation",
      "C": "Saturable glomerular filtration at peak concentration",
      "D": "Stable enterohepatic recycling inherent to the molecule"
    },
    "answer": "A",
    "explanation": "Surfactants/osmogens (e.g., PEGs, polysorbates, mannitol) can alter luminal transit, solubilization, or permeability, generating a secondary absorption pulse in certain formulations only. Options B and C are formulation-agnostic; D would occur across formulations."
  },
  {
    "ID": 80,
    "concept": "CR formulation with programmed biphasic release",
    "pk_curve": "```markdown\n| Time (h) | Conc (µM) |\n|----------|-----------|\n| 0.0      | 0.0       |\n| 1.0      | 2.6       |\n| 2.0      | 7.8       |\n| 4.0      | 4.0       |\n| 6.0      | 6.9       |\n| 8.0      | 3.5       |\n| 12.0     | 2.4       |\n| 16.0     | 1.8       |\n```",
    "question": "CR capsule engineered to provide an initial burst then a programmed second release at ~6 h. What is the most defensible explanation for the early peak and a later scheduled second peak with a CR capsule?",
    "options": {
      "A": "Biphasic release kinetics designed into the dosage form",
      "B": "Transient hepatic congestion increasing bioavailability",
      "C": "Postural changes altering renal excretion",
      "D": "Acute displacement from plasma proteins by food"
    },
    "answer": "A",
    "explanation": "A CR capsule designed with an IR subunit followed by a timed-release core yields two predictable peaks. Physiological explanations (B–D) are not programmed and would not consistently reproduce the same timing."
  },
  {
      "id": 81,
      "concept": "Michaelis–Menten elimination (saturable clearance)",
      "pk_curve": "```markdown\nDose-dependent plasma concentration–time profile (mean values):\n| Time (h) | Conc @ 50 mg (µg/mL) | Conc @ 200 mg (µg/mL) |\n|----------|----------------------|-----------------------|\n| 1        | 15                   | 60                    |\n| 4        | 6                    | 40                    |\n| 12       | 1.5                  | 18                    |\n| 24       | 0.3                  | 8                     |\n```",
      "question": "The table shows nonlinear elimination: AUC increases more than dose proportionally. Which explanation best fits the observation?",
      "options": {
        "A": "Zero-order absorption predominates at low doses",
        "B": "Michaelis–Menten elimination due to enzyme saturation",
        "C": "Protein-binding displacement at higher doses",
        "D": "First-pass metabolism variability"
      },
      "answer": "B",
      "explanation": "Clear supra-proportional rise in exposure when dose increases indicates saturable metabolism consistent with Michaelis–Menten kinetics."
    },
    {
      "id": 82,
      "concept": "Half-life variability with concentration",
      "pk_curve": "```markdown\nSingle dose decay profiles:\n| Time (h) | Conc @ 50 mg (µg/mL) | Conc @ 500 mg (µg/mL) |\n|----------|----------------------|-----------------------|\n| 2        | 8                    | 70                    |\n| 8        | 1.5                  | 40                    |\n| 24       | 0.2                  | 20                    |\n```",
      "question": "Compared to low dose, the high-dose curve shows a longer apparent half-life. What is the mechanistic explanation?",
      "options": {
        "A": "Delayed gastric emptying at high doses",
        "B": "Renal tubular reabsorption is saturated at low dose",
        "C": "Metabolic clearance saturation prolongs elimination at high dose",
        "D": "Bioavailability decreases at high doses"
      },
      "answer": "C",
      "explanation": "At high concentrations, metabolizing enzymes saturate, reducing clearance and prolonging half-life."
    },
    {
      "id": 83,
      "concept": "AUC–dose nonlinearity",
      "pk_curve": "```markdown\nObserved AUC vs Dose:\n| Dose (mg) | AUC (µg·h/mL) |\n|-----------|---------------|\n| 50        | 200           |\n| 100       | 500           |\n| 200       | 1400          |\n```",
      "question": "Which pharmacokinetic parameter is changing with dose to explain these AUC values?",
      "options": {
        "A": "Volume of distribution increases with dose",
        "B": "Clearance decreases with dose due to saturation",
        "C": "Absorption fraction decreases with dose",
        "D": "Elimination half-life decreases with dose"
      },
      "answer": "B",
      "explanation": "The disproportionate rise of AUC with dose indicates clearance decreases as dose increases, typical for nonlinear saturable clearance."
    },
    {
      "id": 84,
      "concept": "Cmax–dose disproportionality",
      "pk_curve": "```markdown\nObserved Cmax vs Dose:\n| Dose (mg) | Cmax (µg/mL) |\n|-----------|--------------|\n| 50        | 8            |\n| 200       | 60           |\n| 400       | 160          |\n```",
      "question": "Cmax rises more than proportionally with dose. What mechanism explains this?",
      "options": {
        "A": "Saturable first-pass metabolism",
        "B": "Increased clearance at higher doses",
        "C": "Reduced absorption at high doses",
        "D": "Time-dependent induction"
      },
      "answer": "A",
      "explanation": "Saturable first-pass metabolism reduces presystemic loss at higher doses, producing greater-than-proportional Cmax increases."
    },
    {
      "id": 85,
      "concept": "Nonlinear steady-state accumulation",
      "pk_curve": "```markdown\nConcentration after daily dosing:\n| Day | Trough Conc (µg/mL) |\n|-----|---------------------|\n| 1   | 1.0                 |\n| 3   | 5.0                 |\n| 7   | 20.0                |\n```",
      "question": "Steady-state trough concentrations rise disproportionately over time. Which mechanism best explains this accumulation pattern?",
      "options": {
        "A": "Time-dependent decrease in absorption",
        "B": "Saturable elimination leading to accumulation",
        "C": "Autoinduction of metabolism",
        "D": "Increased distribution volume"
      },
      "answer": "B",
      "explanation": "The progressive accumulation beyond linear expectation indicates nonlinear saturation of elimination."
    },
    {
      "id": 86,
      "concept": "Dose-dependent bioavailability",
      "pk_curve": "```markdown\nOral dosing, observed F:\n| Dose (mg) | AUC (µg·h/mL) | Expected linear AUC |\n|-----------|---------------|---------------------|\n| 50        | 200           | 200                 |\n| 200       | 1200          | 800                 |\n```",
      "question": "The oral AUC is greater than expected at high dose compared to IV. Which phenomenon explains this?",
      "options": {
        "A": "Nonlinear increase in Vd",
        "B": "Saturable presystemic metabolism, increasing F",
        "C": "Reduced clearance from renal saturation",
        "D": "Formulation-dependent delayed absorption"
      },
      "answer": "B",
      "explanation": "Saturable gut/liver first-pass metabolism results in higher oral bioavailability at higher doses, explaining AUC > linear prediction."
    },
    {
      "id": 87,
      "concept": "Target-mediated drug disposition (TMDD)",
      "pk_curve": "```markdown\nObserved profiles:\n| Dose (mg) | C0 (µg/mL) | t1/2 (h) |\n|-----------|------------|----------|\n| 10        | 2          | 2        |\n| 200       | 40         | 15       |\n```",
      "question": "At low doses, elimination is very fast; at higher doses, half-life is much longer. What mechanism explains this behavior?",
      "options": {
        "A": "Saturable absorption",
        "B": "Target-mediated drug disposition with receptor saturation",
        "C": "Increased renal clearance at higher dose",
        "D": "Autoinduction of metabolism"
      },
      "answer": "B",
      "explanation": "Target-mediated drug disposition: at low concentrations rapid receptor-mediated clearance dominates, but receptor sites saturate at high doses, slowing clearance."
    },
    {
      "id": 88,
      "concept": "Concentration-dependent protein binding saturation",
      "pk_curve": "```markdown\nFree fraction (fu) vs Total conc:\n| Total conc (µg/mL) | fu |\n|--------------------|----|\n| 1                  | 0.05 |\n| 20                 | 0.20 |\n| 100                | 0.40 |\n```",
      "question": "What effect does this nonlinear protein binding have on observed pharmacokinetics?",
      "options": {
        "A": "Apparent clearance decreases at high concentration",
        "B": "Apparent clearance increases at high concentration",
        "C": "Volume of distribution decreases with dose",
        "D": "Half-life remains constant"
      },
      "answer": "B",
      "explanation": "As fu increases with concentration, more free drug is available for clearance processes, raising apparent clearance."
    },
    {
      "id": 89,
      "concept": "Nonlinear renal clearance saturation",
      "pk_curve": "```markdown\nRenal excretion:\n| Dose (mg) | Ae (mg) | CLr (L/h) |\n|-----------|---------|-----------|\n| 50        | 40      | 4.0       |\n| 200       | 100     | 2.0       |\n```",
      "question": "Renal clearance decreases as dose increases. Which mechanism explains this observation?",
      "options": {
        "A": "Saturable active secretion transport",
        "B": "Increased glomerular filtration rate",
        "C": "pH-dependent passive reabsorption saturation",
        "D": "Enhanced tubular flow at high doses"
      },
      "answer": "A",
      "explanation": "At higher concentrations, transporters mediating secretion are saturated, reducing renal clearance."
    },
    {
      "id": 90,
      "concept": "Nonlinear accumulation due to time-varying clearance",
      "pk_curve": "```markdown\nMultiple daily dosing, steady-state trough:\n| Day | Trough (µg/mL) |\n|-----|----------------|\n| 1   | 2              |\n| 3   | 8              |\n| 7   | 40             |\n| 14  | 90             |\n```",
      "question": "Clearance decreases over time, leading to progressive accumulation. Which phenomenon best explains this?",
      "options": {
        "A": "Autoinduction of metabolism",
        "B": "Time-dependent enzyme inhibition",
        "C": "Improved renal function with treatment",
        "D": "Protein binding saturation reducing free fraction"
      },
      "answer": "B",
      "explanation": "Progressive accumulation indicates clearance decreases with time; time-dependent enzyme inhibition explains this trend."
    },
    {
      "id": 91,
      "concept": "Rapid distribution phase and short half-life",
      "pk_curve": "```markdown\nIV bolus concentrations:\n| Time (min) | Conc (ng/mL) |\n|------------|--------------|\n| 1          | 120          |\n| 5          | 40           |\n| 15         | 12           |\n| 30         | 3            |\n```",
      "question": "This profile shows a steep early decline followed by rapid elimination. Which factor is MOST consistent with this pattern?",
      "options": {
        "A": "Large volume of distribution with slow clearance",
        "B": "Extensive tissue distribution and rapid clearance",
        "C": "Enterohepatic recirculation",
        "D": "Saturable elimination"
      },
      "answer": "B",
      "explanation": "The sharp decline followed by low concentrations suggests fast distribution into tissues plus rapid clearance, consistent with adrenaline PK."
    },
    {
      "id": 92,
      "concept": "Short-lived drug requiring continuous infusion",
      "pk_curve": "```markdown\nPlasma concentrations after IV bolus 5 mg:\n| Time (min) | Conc (ng/mL) |\n|------------|--------------|\n| 0.5        | 80           |\n| 2          | 25           |\n| 5          | 5            |\n| 10         | 1            |\n```",
      "question": "Given the very short half-life, which dosing strategy is most effective to maintain therapeutic concentrations?",
      "options": {
        "A": "Once-daily bolus dosing",
        "B": "Continuous IV infusion",
        "C": "Oral sustained release formulation",
        "D": "Intramuscular injection every 12 h"
      },
      "answer": "B",
      "explanation": "Rapid elimination means plasma levels fall quickly. Continuous infusion maintains effective concentration better than bolus or intermittent routes."
    },
    {
      "id": 93,
      "concept": "High variability between subjects",
      "pk_curve": "```markdown\nConcentrations after 10 mg IM dose:\nSubject A: Tmax = 10 min, Cmax = 25 ng/mL\nSubject B: Tmax = 20 min, Cmax = 10 ng/mL\nSubject C: Tmax = 5 min, Cmax = 35 ng/mL\n```",
      "question": "What is the most likely explanation for variability in Tmax and Cmax among individuals?",
      "options": {
        "A": "Differences in systemic clearance",
        "B": "Differences in absorption rate and local blood flow",
        "C": "Differences in tissue protein binding",
        "D": "Differences in enzyme saturation"
      },
      "answer": "B",
      "explanation": "For IM absorption, local perfusion largely dictates Tmax and Cmax, explaining the variability across subjects."
    },
    {
      "id": 94,
      "concept": "Flip-flop kinetics misinterpretation",
      "pk_curve": "```markdown\nOral dosing 20 mg:\n| Time (h) | Conc (ng/mL) |\n|----------|--------------|\n| 0.25     | 5            |\n| 0.5      | 10           |\n| 1        | 8            |\n| 2        | 4            |\n| 4        | 1            |\n```",
      "question": "Which statement best explains why the terminal slope reflects absorption rather than elimination?",
      "options": {
        "A": "Elimination is faster than absorption, causing flip-flop kinetics",
        "B": "Elimination rate is slower than absorption",
        "C": "Drug is saturating transporters",
        "D": "Drug is undergoing enterohepatic recirculation"
      },
      "answer": "A",
      "explanation": "When absorption is slower than elimination, the terminal slope of the concentration curve is governed by absorption, characteristic of flip-flop kinetics."
    },
    {
      "id": 95,
      "concept": "Oral bioavailability vs. IV dosing",
      "pk_curve": "```markdown\nIV 10 mg → AUC = 50 ng·h/mL\nOral 20 mg → AUC = 25 ng·h/mL\n```",
      "question": "What is the estimated oral bioavailability (F)?",
      "options": {
        "A": "25%",
        "B": "50%",
        "C": "75%",
        "D": "100%"
      },
      "answer": "A",
      "explanation": "F = (AUC_oral / Dose_oral) / (AUC_IV / Dose_IV). = (25/20) / (50/10) = 1.25 / 5 = 0.25 → 25%."
    },
    {
      "id": 96,
      "concept": "Short Tmax reflecting rapid absorption",
      "pk_curve": "```markdown\nOral solution dosing:\n| Time (min) | Conc (ng/mL) |\n|------------|--------------|\n| 5          | 18           |\n| 10         | 30           |\n| 20         | 12           |\n| 40         | 4            |\n```",
      "question": "What does a very short Tmax (10 min) most likely reflect?",
      "options": {
        "A": "Extremely rapid absorption into systemic circulation",
        "B": "Very slow elimination",
        "C": "Low volume of distribution",
        "D": "Saturable protein binding"
      },
      "answer": "A",
      "explanation": "The early Tmax reflects rapid absorption rather than elimination or distribution factors."
    },
    {
      "id": 97,
      "concept": "Non-compartmental analysis pitfalls",
      "pk_curve": "```markdown\nObserved profile:\n| Time (h) | Conc (ng/mL) |\n|----------|--------------|\n| 0.05     | 90           |\n| 0.25     | 30           |\n| 1        | 5            |\n| 3        | 1            |\n```",
      "question": "What is the biggest risk when applying log-linear terminal extrapolation to estimate AUC here?",
      "options": {
        "A": "Overestimation of AUC due to long sampling",
        "B": "Underestimation of AUC if early distribution phase is misinterpreted as elimination",
        "C": "Misinterpretation of absorption phase",
        "D": "Failure to estimate Tmax"
      },
      "answer": "B",
      "explanation": "If the distribution phase is mistaken as elimination, the λz will be overestimated, biasing extrapolated AUC downward."
    },
    {
      "id": 98,
      "concept": "Multiple dosing with no accumulation",
      "pk_curve": "```markdown\nOral 5 mg given every 8 h for 3 days:\nDay 1 Cmin ≈ 0.5 ng/mL\nDay 3 Cmin ≈ 0.5 ng/mL\n```",
      "question": "What explains the absence of accumulation despite repeated dosing?",
      "options": {
        "A": "Extensive protein binding prevents accumulation",
        "B": "Short half-life compared to dosing interval",
        "C": "Saturable metabolism",
        "D": "Low volume of distribution"
      },
      "answer": "B",
      "explanation": "When half-life is much shorter than dosing interval, the drug is cleared before the next dose, preventing accumulation."
    },
    {
      "id": 99,
      "concept": "Nonlinear PK misinterpretation",
      "pk_curve": "```markdown\nDose vs AUC:\n| Dose (mg) | AUC (ng·h/mL) |\n|-----------|---------------|\n| 1         | 5             |\n| 5         | 50            |\n| 10        | 200           |\n```",
      "question": "Which mechanism is MOST consistent with the disproportionate increase in AUC at higher doses?",
      "options": {
        "A": "Saturable elimination pathway",
        "B": "Autoinduction of metabolism",
        "C": "Decreased absorption fraction",
        "D": "Linear first-order clearance"
      },
      "answer": "A",
      "explanation": "The supra-proportional AUC rise with dose is typical of saturable elimination, not induction or decreased absorption."
    },
    {
      "id": 100,
      "concept": "Short-lived drug effect vs plasma concentration",
      "pk_curve": "```markdown\nIV bolus:\n| Time (min) | Conc (ng/mL) | Effect (% of max) |\n|------------|--------------|-------------------|\n| 1          | 100          | 90                |\n| 5          | 30           | 60                |\n| 15         | 8            | 10                |\n| 30         | 2            | 0                 |\n```",
      "question": "The effect disappears nearly as quickly as plasma concentrations decline. What does this suggest about PK/PD relationship?",
      "options": {
        "A": "Hysteresis due to active metabolite",
        "B": "Direct PK/PD relationship with no delay",
        "C": "Counter-clockwise hysteresis due to distribution to effect site",
        "D": "Tachyphylaxis independent of PK"
      },
      "answer": "B",
      "explanation": "The rapid parallel decline in concentration and effect suggests a direct PK/PD relationship without significant hysteresis."
    }
  ]
